A Sermorelin listing still leaves conditions to check.
The prescription, the pharmacy's rules and FDA approval answer different questions. Here's how to keep them apart without a law degree.
If it's listed online.
The clinician can still say no.
A medicine appearing on a website doesn't mean a prescription is waiting for you. A clinician has to review the request. “Available” describes a possible route, not the outcome of that review.
Promise Peptides has a current Sermorelin prescription route at mypromise.com, using a compounded preparation. U.S.-licensed providers assess requests and may decline them; not everyone qualifies. Location restricts care to U.S. patients, and the particular state and treatment can narrow availability further. The compounded medicine isn't FDA-approved; this describes the route without recommending it for you.
Location matters because state licensing requirements differ. An online appointment doesn't erase those requirements. The person's review and the rules where care happens both remain part of access.
If someone says it was approved.
Keep the old product in the sentence.
Sermorelin was sold as Geref for specialist hormone testing and certain childhood growth problems. Those weren't approvals for adult fat loss, better sleep or general vitality.
The maker stopped selling it in 2008. FDA withdrew the approvals in 2009. In its 2013 finding, FDA said the products hadn't left sale for safety or effectiveness reasons. That corrects a common misunderstanding; it doesn't approve a pharmacy-made product today.
So “once approved” needs more than a nod. Which product and which use? Keeping those details nearby prevents a true bit of history from suggesting something it doesn't mean.
If a pharmacy makes it.
The ingredient matters, and so do the other rules.
Under FDA's section 503A rules, a raw ingredient must meet an applicable USP or NF monograph, meaning an official quality standard, and the USP chapter on pharmacy compounding. If no monograph exists, the ingredient must be part of an approved drug; failing that, it must appear on FDA's 503A ingredient list. It also needs a valid certificate of analysis and an FDA-registered manufacturer.
Why “Sermorelin acetate”? That's the form Geref used. FDA's 503B list for registered outsourcing facilities identifies it as an approved-drug ingredient. Those facilities follow a different part of the law from 503A pharmacies. FDA's 503A guidance explains the approved-drug ingredient route using the Orange Book, which includes discontinued products.
On that reading, a state-licensed pharmacy may have a basis to prepare Sermorelin acetate for a named patient with a prescription. Every other federal and state condition still applies. This isn't a Sermorelin-specific FDA clearance under 503A, or a ruling about any particular pharmacy.
The finished compounded medicine remains unapproved. General information can explain the distinction; it can't replace legal or medical advice about an actual arrangement.